Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Invested Capital (2016 - 2025)

Historic Invested Capital for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $920.2 million.

  • Catalyst Pharmaceuticals' Invested Capital rose 3923.25% to $920.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $920.2 million, marking a year-over-year increase of 3923.25%. This contributed to the annual value of $727.6 million for FY2024, which is 8759.16% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Invested Capital is $920.2 million, which was up 3923.25% from $856.0 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Invested Capital high stood at $920.2 million for Q3 2025, and its period low was $178.7 million during Q1 2021.
  • In the last 5 years, Catalyst Pharmaceuticals' Invested Capital had a median value of $348.5 million in 2023 and averaged $441.0 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Invested Capital soared by 2195.37% in 2021, and later soared by 8962.7% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Invested Capital (Quarter) stood at $206.8 million in 2021, then skyrocketed by 45.25% to $300.4 million in 2022, then grew by 29.11% to $387.9 million in 2023, then skyrocketed by 87.59% to $727.6 million in 2024, then rose by 26.47% to $920.2 million in 2025.
  • Its Invested Capital stands at $920.2 million for Q3 2025, versus $856.0 million for Q2 2025 and $794.3 million for Q1 2025.